Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Helen Sheridan

Fellow Emeritus (Pharmacy)
      
Profile Photo

Professor Helen Sheridan

Fellow Emeritus (Pharmacy)

 hsheridn@tcd.ie

 


Helen Sheridan BSc (UCD), PhD (UCD), is Professor in Pharmacognosy and former Director of Research at the School of Pharmacy and Pharmaceutical Sciences (SoPPS) at TCD. She is the academic founder and director of the TCD centre for natural product research, NatPro. She is a Fellow of Trinity College Dublin and the Royal Society of Chemistry; a recipient of the TCD Provost's award for teaching excellence and a recipient of the TCD Innovation Award for 'Societal Impact'. Helen has over 100 publications including 7 international patents. She has mentored 35 PhD/ MSc students and 26 postdoctoral researchers. She was awarded 19 million euro in grant income from national and international sources. Helen's collaborative and interdisciplinary research is in Natural Product (NP) chemistry; Traditional Medicine (TM); ethnopharmacology; global health and bioeconomy. Her research focusses on finding new therapies for disease and addressing global issues that may be resolved using NP approaches. During her career she identified a lead molecule which her team advanced from discovery to human clinical trials. Helen co-founded the TCD Campus company, Trino Therapeutics Ltd, and was co-PI on funding of approximately 13 million euro. She was also co-applicant on seven patents in the US, EU and Asia. In later years Helen has become involved in global ethnopharmacology, investigating quality, safety and efficacy of TMs, and the link between the established use of TM and its role in international development. She has supervised 5 research projects in sub-Saharan Africa. Helen was recently awarded €6M to direct a project entitled 'Unlocking Nature's Pharmacy from Bogland Species' focused on the therapeutic and economic potential of the Irish bog land plants, from scientific and educational perspectives. She is a collaborator on the HEI funded IKC3 project €3.5m. Helen was the Phytochemical expert to the Irish Health Products Regulatory Authority (HPRA) for over 20 years and remains as a clinical advisor. She is on the Board of the International Natural Product Sciences taskforce (INPST); the Board of the GP-TCM Research Association; and most recently was appointed by the Cross-Government Bioeconomy Implementation Group (BIG) to the Expert Advisory Group (CECC and DAFM), as the expert in NP science, to support the National Bioeconomy Forum. Helen holds a TCD award for excellence in teaching. She has taught at all levels across the SoPPS curriculum and has contributed to courses across faculties. Her teaching is research led, maps frontier developments, is informed by government policy and international regulation, and is aligned with global development goals. Her course design and delivery involve synergy at the interfaces governing her discipline. She has recently been funded by the IRC New Foundations scheme, to build educational and research collaborations between TCD, and Maseno University (Kenya). This project which involves bi-lateral travel, is on hold until the Covid situation has stabilised. Helen has held senior administrative positions in College, including Director of Research SoPPS (2016-9); Academic Disability Liaison Officer (2006-To date); positions in safety at school, faculty and college level and is the faculty representative on the College Safety Committee. She was faculty representative on the Trinity International Development Initiative steering committee. Helen has acted as external examiner to the School of Pharmacy in UCL (2015-8); has examined at masters and PhD level nationally and globally; has acted as an international grant reviewer on several programmes. Helen is engaged in outreach with a range of stakeholders. Most recently she and her group have launched a national programme for Transition Year students looking at biodiversity and scientific potential of bogland ecosystems. Over 8,000 students have engaged with this programme. Helen hopes her research, teaching, and outreach will make a difference to society.
  ALTERNATIVE MEDICINE   Antiinflammatory drugs   Autoimmune Diseases (Multiple Sclerosis, Rheumatoid Arthritis)   Biotransformation   Chemical Biology   Development of drugs for malaria, Cancer and inflammatory diseases   Drug discovery   Fungi   Herbal medicine   In Vitro Testing, Trial Methods   Indanes, indanones, muscel, nast cell stabilisation, immunosuppressants   Inflammation   Inflammatory Bowel Disease   Medicinal plants   Multiple Sclerosis   Natural Product Chemistry   Organic chemistry   Over-the-Counter Drugs   Pharmacognosy   Phytochemical and pharmacological evaluations of native and foreign plants   Phytomedicines   Plant and algal cell monocultures   Secondary plant metabolism   The use of cell cultures for the discovery of novel drugs   Traditional and Indigenous health systems in developing countries   Traditional Chinese Medicine
Project Title
 Unlocking Nature's Pharmacy from Bogland Species
From
December 2019
To
Jan 2024
Summary
"Unlocking Nature's Pharmacy from Bogland Species" is a project focused on studying the potential of the Irish bog plants. Bogs of Ireland constitute an enormous national resource. The cessation of industrial harvesting of bogland provides a unique opportunity to unlock the potential of bogland species and thus confer socio-economic and ecological and educational benefits to local communities and nationally. The aim of this project is to investigate the potential of the flora of the Irish boglands as a source of novel plant derived therapeutic formulae. Plant species, native to these environments, may provide an environmental and economic solutions to the future of these resources and to the communities who have worked on them. The project will be led by Principal Investigator, Professor Helen Sheridan of the School of Pharmacy and Pharmaceutical Sciences (SoPPS). The SoPPS at TCD is ranked number 34 by the Shanghai Ranking's Global Ranking of Academic Subjects 2018 - Pharmacy & Pharmaceutical Sciences (July 2018). Professor Sheridan is Ireland's leading academic in the area of Natural Product Chemistry. She has been pivotal in the development of new medicines using plants and cell cultures (plant, fungal and animal). Professor Sheridan is a founding and life member of an international Sino/European consortium, funded under EU-FP7, working on the application of quality, safety and efficacy of Traditional Medicines. She will work with teams across Trinity, and with her international collaborators to deliver this ambitious and pioneering research.
Funding Agency
Chinese Investors / Department of Justice
Programme
IIP Programme
Project Type
Research and Outreach
Project Title
 Formulation development of natural products (NPs) from therapeutic plants
From
September 2021
To
August 2025
Summary
This project is funded by the EPSRC-SFI Centre for Doctoral Training (CDT) in Transformative Pharmaceutical Technologies and will link the SSPC (The Science Foundation Ireland Research Centre for Pharmaceuticals) and Trinity's NatPro Research Centre. The project will be concerned with two particular aspects: 1. Using a metabolomics approach in the assessment of the impact of pharmaceutical manufacturing processing technologies on the phyto-chemical profile and thereby potentially the biological activity of plant species of interest. 2. Assessment of the potential for the use of different "solidification" methods to convert NP extracts and tinctures of interest to powdered materials suitable for inclusion in a drug product (DP) or nutraceutical product (NCP) formulation. The overall objective of the project is to ascertain suitable processing and formulation approaches that can be employed to harness the potential of natural products (NPs) of interest, and to establish a platform product development train that can be applied to multiple NP extracts or tinctures.
Funding Agency
EPSRC-SFI Centre for Doctoral Training (CDT)
Programme
Transformative Pharmaceutical Technologies
Project Type
Interdisciplinary - Technology applied to Natural Product
Person Months
48
Project Title
 Functional Food and Pharmaceuticals - Marine Micro-Algae
From
2020
To
2022
Summary
This Marie Curie Career-Fit PLUS project, under H2020 and EI, aims to directly characterise algal key regulatory genes, for example to stop and start lipid biosynthesis. This is an emerging field with great potential for micro-algal cultivation for pharmaceuticals and human nutraceuticals. This research takes advantage of an unprecedented visualisation of lipid droplet change and current state of the art of proteomics and metabolomics to answer questions at the leading edge of algal biology.
Funding Agency
EU - EI
Programme
Marie Curie Career fit programme
Project Type
Interdisciplinary natural product research
Person Months
24
Project Title
 Identification and characterisation quinoa strains with high antiinflammatory activity
From
September 2021
To
August 2025
Summary
The intestinal epithelium lines the gastrointestinal tract and forms a protective barrier separating us from the gut contents. If this barrier breaks down, bacteria, allergens, and toxins can enter the gut wall causing inflammation and, if left unchecked, can lead to the development of inflammatory bowel disease (IBD) and colorectal cancer (CRC). While drugs (e.g., steroids and immunosuppressants) can dampen inflammation, they are often limited by expense, side effects, or lack of response. Therefore, new treatment approaches are urgently needed and given the enormous costs associated with pharmaceutical development, researchers are turning their attention to nutraceuticals as an alternative approach. Nutraceuticals are defined as food components that provide health benefits. Many come from dietary plants already used for centuries in traditional medicine and now increasingly used in Western countries, where nutraceutical sales are expected to exceed $200 billion by 2022. Despite this, knowledge of how bioactive molecules in nutraceuticals, known as phytochemicals (e.g., terpenes and flavonoids), exert their anti-inflammatory effects is still poor. Quinoa (Chenopodium quinoa Wild.), the "Golden grain of the Andes", is an ancient seed crop originally grown by Peruvian Aztecs. Designated a "superfood" in 2013 by the WHO, demand for quinoa has since surpassed supply, so that there is now a global shortage. Quinoa is highly nutritious and the only plant food containing all essential amino acids, trace elements and vitamins. It is also very rich in anti-inflammatory phytochemicals. Recently, Glanbia tested quinoa as a food crop in Ireland and, finding it to grow well in our climate, now have 8 different cultivars. FXR is a receptor protein expressed in intestinal epithelium where it is an important regulator of inflammation, cancer growth, and metabolism. In fact, reduced epithelial expression of FXR is associated with IBD, CRC, and metabolic diseases (9-11). Interestingly, studies from the Supervisor's labs have shown that an extract of quinoa increases FXR expression and activation in colonic epithelial cells (Figure 1). With this in mind, the central hypothesis of this project is that, by virtue of their anti-inflammatory and FXR-modulating actions, quinoa extracts can be developed as a new class of nutraceutical to prevent intestinal inflammation.
Funding Agency
IRC-Glanbia - EPS Scheme
Programme
IRC
Project Type
Interdisciplinary research - Natural Products and gut health
Person Months
48
Project Title
 Assessment of the therapeutic potential of two lead anti-inflammatory molecules with a novel carbon scaffold in ex-vivo colonic explant tissue.
From
July 2018
To
October 2019
Summary
The rigid bicyclic indane (2,3-dihydro-1H-indene) is a 'privileged' sub-structure offering ten potential substitution sites for the design of high-affinity ligands with a 'perfect fit', targeted at a range of receptors. Elaborated indane scaffolds are in clinical use, including: Donepezil (Aricept) a reversible ACE inhibitor and Sulindac (Clinoril) an anti-inflammatory of unknown mechanism. Our ongoing research has led to the discovery of a commercially accessible, novel indane scaffold. 24 analogues (mwt <350) have been synthesised (4-5 steps) from inexpensive starting materials. We have identified two lead molecules which demonstrate anti-inflammatory and anti-angiogenic effects in-vitro. Based on our results, we wish to evaluate their effects on mediators in ex-vivo human ulcerative colitis explants together with their modulating effects on the tumour microenvironment. We anticipate that these lead molecules, alone or as combination with current therapies will reduce the immunosuppressive phenotype of the tumour microenvironment. There is potential for these molecules to treat disease such as IBD, RA, psoriasis; certain forms of cancers e.g. Barrett's oesophagus and also orphan diseases, such as Castleman's disease.
Funding Agency
SFI
Programme
TIDA
Project Type
Biomedical research and drug discovery
Person Months
12

Page 1 of 3
Details Date
External examiner to the University of Westminster. UK December 2021
Member of an Expert Advisory Group to support the National Bioeconomy Forum August 2021
Elected Board member of the Good Practice in Traditional Chinese Medicine Research International Association (GP-TCM) August 2021
Grant evaluator for the ​Swiss National Science Foundation (SNSF) 2021
Expert on Advisory Board to the European Innovation Partnership -The Cultural Heritage of the Comeragh Mountains. June 2021
Academic Director of the NatPro The TCD Centre for Natural Product Research November 2019
Founder of 'NatPro', the TCD Centre for Natural Product Research and development December 2019
External Examiner to Postgraduate taught Master's Degrees in University College London (4 year term) 2015-2018
Founder of the TCD spinout company Trino Therapeutics Ltd 2000
Natural Product advisor to the Health Products Regulatory Authority (HPRA) Herbal Medicines Sub-Committee 2006 to date
Irish Medicines Board Traditional Herbal Medicinal Products Ad Hoc sub-committee. 2000 - 2006
Board Member of the International Natural Product Science taskforce 2017 - To date
Grant evaluator: International Foundation for Science, Sweden; http://www.ifs.se/ 2009 to date
Grant evaluator for the Medical Research Council UK 2012
External Examiner to Victoria University of Wellington. Wellington, New Zealand 2014
External examiner for the University of Westminster. UK Autumn 2021
Examiner University College London 2019
External Examiner Cardiff University PhD Thesis 1991
Examiner King's College London 2019
Youth Science committee of the Royal Dublin Society 1990-1992
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Medium Medium Medium
Details Date From Date To
Elected Board member of the Good Practice in Traditional Chinese Medicine Research Association (GP-TCM) Jan 2020 2022
Fellow of the Royal Society of Chemistry. 1989 To date
Board member of the Board of Directors of the Natural Product Sciences Task force INPST https://inpst.net/. 2016 To date
Life member GP-TCM RA (Good Practice in TCM Research Association). 2009 To date
Member of the Society for Medicinal Plant and Natural Product Research. Gesellschaft für Arzneipflanzen- und Naturstoff-Forschung e.V. (GA). 2014 To date
Member of the SCT (Societe De Chimie Therapeutique The French Society for Medicinal Chemistry) 2014 To date
NPRONET: Natural products discovery and bioengineering network 2017 to date
Tao Zhang, Kit Chan, Abdulilah ECE, Robin Daly, Aoife Cannon, Neil Frankish, Jacintha O'Sullivan, Padraig Fallon, Helen Sheridan, Bioactive Indanes: Design, Synthesis and Bioactivity Investigation of 2,2-Substituted Indane Derivatives, a New Bioactive Indane Scaffold, Bioorganic Chemistry, 2025, Journal Article, IN_PRESS
Reda El Boukhari et al., Helen Sheridan et al., Atanas G. Atanasov, Enhancing human gut health: global innovations in dysbiosis management, iMeta, 2025, Journal Article, IN_PRESS
Rajeev K. Singla [........] Helen Sheridan ..[....]Bairong Shen, Exploring nutritional supplement use for Countering respiratory tract infections through an"X"(formerly Twitter)-based survey, Current Research in Biotechnology, 2025, Journal Article, PUBLISHED
Erol, Ã-zlem and Nagar, Shipra and Selo, Mohammed Ali and Obaidi, Ismael and Walsh, John J. and Sheridan, Helen and Choi, Young Hae, Identification of anti-inflammatory and antimicrobial compounds from leaves and rhizome of Iris pseudacorus collected in Ireland bogland using chemical profiling techniques, Fitoterapia, 185, 2025, Notes: [Cited by: 0], Journal Article, PUBLISHED  DOI
Kate Tolan, Mohammed Ali Selo, Ismael Obaidi, Peter O'Connell, Michael Carty, Shipra Nagar, Anne Marie Healy, Helen Sheridan, The effects of upstream processing on the chemical profile and immunomodulating activity of Echinacea purpurea tinctures, Phytochemistry Letters, 68, 2025, 102971, Journal Article, PUBLISHED  TARA - Full Text  DOI
Jabal, Khadijah A. and Pigott, Maria and Sheridan, Helen and Walsh, John J., Mediterranean Basin Erica Species: Traditional Uses, Phytochemistry and Pharmacological Properties, Molecules, 30, (12), 2025, Notes: [Cited by: 0], Journal Article, PUBLISHED  DOI
Sumin Seo, Hye Kyong Kim, Hye Kyong Kim, Harald van Mil, Jeeyoun Jung, Young Pyo Jang, Dae"Young Lee, Mei Wang, Helen Sheridan, Sang Beom Han, Young Hae Choi, Leveraging Metabolic Similarity in a ¹H NMR Database of Medicinal Plants: A Macroscopic Approach to Advancing Pharmacognostic Insights, 2025, Journal Article, PUBLISHED  DOI
Jessica S. Smyth, Ciara M. Fallon, Helen Sheridan, Stephen J. Keely, Upregulation of Farnesoid X Receptor expression and activity in colonic epithelial cells by a lipid-based plant extract, Physiology, 40, (S1), 2025, Journal Article, PUBLISHED  DOI
Özlem Erol, Shipra Nigar, Mohammed Ali Selo, Helen Sheridan, Young Hee Choi, Unlocking nature"s pharmacy: Iris pseudacaros from Ireland as potential source for antimicrobial and anti-inflammatory compounds, Phytochemistry Letters, 69, 2025, p103312 - 103312, p103312-103312 , Journal Article, PUBLISHED  DOI
Sophie Whyms, Gaia Scalabrino, Kate Connor, Shipra Nagar, Maria Pigott, Helen Sheridan, Mark O. Cunningham, Assessment of the anticonvulsant activity of Myrica gale L., a traditional Irish plant in ethnoveterinary medicine, using a 4-AP induced seizure, electrophysiological model, in vitro, Phytochemistry Letters, 69, 2025, p103575 - 103575, p103575-103575 , Journal Article, SUBMITTED  DOI
  

Page 1 of 18
Fiona Shannon, Astrid Sasse, Michael Heinrich and Helen Sheridan, A repository of knowledge - the Schools' Manuscript Collection, offering a unique insight into medicinal practices in 1930s Ireland, 'Interdisciplinary Approaches to the Study of Healing, Charms and Medicine'. , Department of Celtic languages and literature. Harvard University. , April 5-7th 2018., 2018, Conference Paper, PUBLISHED
Fiona Shannon, Astrid Sasse and Helen Sheridan. , Ethnomedicinal practices in 1930s Ireland. History of Medicine Section of the Royal Academy of Medicine, History of Medicine, Dublin, Ireland, 9th May, 2018, Conference Paper, PRESENTED
Jinfan Wang, Ingrid Hook, Malte Brummerloh, Jandirk Sendker, Astrid Sasse and Helen Sheridan. , From Monograph to Metabolomics: A Scientific Evaluation of the Traditional Chinese Herbal Medicine Houttuynia cordata Thunb (鱼腥草Yu Xing Cao) Saururaceae - a case study, The 6th Annual Meeting of Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA). , Jordell Laboratories. Kew Gradens. London UK, July 4-6th. , 2018, Notes: [Joint First Prize], Conference Paper, PRESENTED
Ciara M Fallon, Jessica Smyth, Natalia Lajczak, Helen Sheridan and Stephen J Keely. , Neutraceutical targeting of the bile acid receptor, farnesoid X receptor, for intestinal disease, The FALK Symposium 211 XXV International Bile Acid Meeting: Bile Acids in Health and Disease. , Dublin, Ireland, July 6 - 7, 2018, Conference Paper, PUBLISHED
J. Wang, Ingrid Hook, Malte Brummerloh, Jandirk Sendker, Astrid Sasse and Helen Sheridan. , Best Practice for the Scientific Evaluation of Traditional Herbal Medicines: Houttuynia cordata Thunb (鱼腥草Yu Xing Cao) Saururaceae - A Case Study. , 66th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) jointly with the 11th Shanghai TCM conference, Shanghai, August 26 - 29, 2018, Conference Paper, PUBLISHED
Helen Sheridan, Fiona Shannon, Astrid Sasse and Michael Heinrich, Insight into Healing Herbs used in Post-famine Ireland, 66th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) jointly with the 11th Shanghai TCM conference, Shanghai, China, August 26 - 29, 2018, Conference Paper, PUBLISHED
Fiona Shannon, Astrid Sasse and Helen Sheridan., A repository of knowledge. The Schools' Manuscript Collection, offering a unique insight into medicinal practices in 1930s Ireland. , London, 2018, The British Society for the History of Pharmacy (BSHP)., Invited Talk, PUBLISHED
Shanahan, F., Michael heinrich, Sasse, A, Sheridan, H., Traditional Medicinal Knowledge in Ireland in the 1930s - Exploring Botanical Treatments. , 58th Annual Meeting of the Society of Economic Botany. L, Braganca, Portugal, 5th June 2017, edited by Conference Committee , 2017, Conference Paper, PUBLISHED
Helen Sheridan , Exploration of the feasibility of setting up the Trinity (or Irish) - Natural Product Foundation (Trinity-NPF of I-NPF) within TCD., CF-2017-0569Y. , Enterprise Ireland, 2017, Report, PUBLISHED
Shanahan, F., Sasse, A, Sheridan, H. , An Ethnomedicinal Study of Traditional Plant Remedies of Co. Wexford, Ireland in the 1930s. , 38th All Ireland Schools of Pharmacy Research Conference. , Royal College of Surgeons, Dublin 2. , 21st March 2016, 1, 2016, P1-, Conference Paper, PUBLISHED

  


Page 1 of 3
Award Date
Trinity Innovation Award in the category 'Societal Impact' December 2021
Government appointment as Natural Product expert to the Expert Advisory Group to the National Bioeconomy Forum July 2021
Selected for participation in the Science Foundation Ireland - National Science Foundation US, for participation in the NSF Innovation Corps (I-CorpsTM) Programme. June 2021
Appointed to Fellowship of Trinity College Dublin -FTCD 20.04.2020
Co-founder NatPro - The TCD Centre for Natural Product Research November 2019
Trinity College Dublin: Trinity Excellence in Teaching Awards - Provost's Teaching Award 2019
SFI TIDA Award 2017
Appointed to Fellowship of The Royal Society of Chemistry 2017
Wellcome Trust Strategic Translation Award (co-PI) 2013
Irish American Partnership Research Award - with Pfizer 1992
Travel awards: British Council 1991
RIA Travelling award 1990
Department of Education Post Doctoral Fellowship (UCD). 1984-1985
Royal Commission for the 1851 Exhibition - Overseas Traveling Scholarship 1983-1984
French Government research Award - CNRS. Gif-Sur-Yvette 1983
NBST Young Researcher award with Dr. Hector Rubelcava (UCD) 1979
My research has always been multidisciplinary; built on collaboration with pharmacologists/ molecular-biologists/ bio-technologists/ botanists/anthropologists and sociologists and is recognised at a national and inter-national level. The driving force behind my work is to find new therapeutic treatments for unmet clinical need and to finding meaningful uses for natural molecules, and to improve the position on communities in the developing world who have a cultural and financial reliance on Traditional Medicine. I have learned a lot about the journey from therapeutic drug discovery to human trials, and the challenges and obstacles that line the road. However, experience led decision making about research is invaluable. Through this lens of experience, the molecules my group is working on have real therapeutic potential and have been designed to eliminate some of the insurmountable obstacles to drug development. My drug discovery focus, has been informed by the natural world, ethnomedical practice across the globe; molecular design, based on hybridised natural molecules; and using computer modelling to find natural molecules that target important receptors. In my natural product research I have engaged with International, multidisciplinary Consortia establishing good practice and gold standards for quality, safety and efficacy of complex natural medicines as nutraceuticals, and as food supplements. One of my core research and teaching beliefs is that 'it is at the interface of disciplines and expertise that new ideas and creativity emerge'. My current research falls under four main themes. 1) Multidisciplinary approach Drug discovery for the treatment of inflammatory disease and cancer Finding new therapies targeted at diseases with unmet clinical need. Currently I am PI on an SFI TIDA award and have 50 molecules being tested at level 2 in the Lilly Open Innovation Platform, with six significant nanomolar hits against a key target in Chemotherapy and radiation resistant cancer cells. 2) Drug discovery from the natural world is still ongoing. We use of natural materials (plants, cell cultures, microalgae) for the discovery of novel bio-active materials. 3) Traditional Herbal Medicine. Overview the best practice methodology, recommend applications, and future directions for metabolic profiling, component analysis and purification of secondary metabolites in preparations utilised in Traditional Medicine by large populations (Asia and Africa). Utilising metabolomic techniques to establish best practice for the determination of quality, safety and efficacy of herbal medicines for human and veterinary use. 4) Exploring traditional medicine (TM) in Ireland and in Sub-Saharan-Africa in the context of a changing global healthcare landscape, using a community in West Pokot, Kenya as a case study. I am Co-founder of Trino Therapeutics (Formerly Pharmatrin ltd), a TCD campus company whose activities are centered on drug discovery/development. Through this vehicle my research progressed through a significant Medicinal Chemistry programme of lead optimisation, GMP synthesis of lead, pre-clinical evaluation, regulatory approval and progression through Phase 1 Clinical trials. My ethnomedical research was presented in Harvard (2018), and my overall research work has been presented internationally and most recently on an invited lecture tour in China.